Avastin — Competitive Intelligence Brief

Avastin (bevacizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vascular Endothelial Growth Factor Inhibitor [EPC]. Area: Oncology.

marketed Vascular Endothelial Growth Factor Inhibitor [EPC] Vascular endothelial growth factor A Oncology Monoclonal antibody

Target snapshot

Avastin (bevacizumab) — Roche. Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Avastin TARGET	bevacizumab	Roche	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]	Vascular endothelial growth factor A	2004-01-01
Vabysmo	FARICIMAB	Roche	marketed		Vascular endothelial growth factor A	2022-01-01
Beovu	BROLUCIZUMAB	Novartis	marketed		Vascular endothelial growth factor A	2019-01-01
Vegf Trap	AFLIBERCEPT	Regeneron	marketed	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	2011-01-01
Macugen	EYE001	Valeant Pharms Llc	marketed		Vascular endothelial growth factor A	2004-01-01
Macugen	pegaptanib	Bausch Health	marketed		Vascular endothelial growth factor A	2004-01-01
Intravitreal ranibizumab	Intravitreal ranibizumab	LEANDRO CABRAL ZACHARIAS	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

• 2026-04-09 — Vabysmo · FDA · approved · US · Roche

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vascular Endothelial Growth Factor Inhibitor [EPC] class)

1. AMGEN INC · 1 drug in this class
2. BIOCON BIOLOGICS INC · 1 drug in this class
3. CELLTRION · 1 drug in this class
4. Roche · 1 drug in this class
5. SANDOZ INC · 1 drug in this class